Final testing of MS drug launchedBiogen Idec said it has launched final, Phase 3 testing of an oral drug to treat multiple sclerosis. The Massachusetts company, which has a research campus in San Diego, said the drug will be tested in more than 2,000 patients in North America. The studies of BG-12, as the drug is known, are expected to last two years. The drug would be the third in Biogen Idec's portfolio of multiple sclerosis medicines. In June, the company reintroduced the drug Tysabri with partner Elan Pharmaceuticals based on a risk-management plan that stipulated it must be administered...